Drug intelligence / Profile preview

benazepril + losartan

Development stage: Discontinued
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of benazepril (an angiotensin-converting enzyme inhibitor) and losartan (an angiotensin II receptor blocker). Both medications are used to treat hypertension but through different mechanisms. Benazepril works by blocking a substance in the body that causes blood vessels to tighten, while losartan blocks the action of angiotensin II. Using these medications together is generally not recommended as standard practice due to increased risk of side effects including low blood pressure, kidney function impairment, and other adverse effects.

Targets

ACE (Angiotensin Converting Enzyme)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on benazepril + losartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on benazepril + losartan.

Explore the full profile